Chronic Lower Back Pain Therapeutics Market Size in the 7MM was ~USD 6,071 million in 2023, estimated DelveInsight

DelveInsight's "Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Lower Back Pain market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Chronic Lower Back Pain Market is an evolving segment of the global healthcare landscape, driven by the increasing Chronic Lower Back Pain prevalence of the disorder and the continuous development of innovative treatment options. The Chronic Lower Back Pain market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

Discover Key Insights into the Chronic Lower Back Pain Market with DelveInsight's In-Depth Report @ Chronic Lower Back Pain Market Size [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Lower Back Pain Market Report

* In November 2024:- Evon Medics LLC- In this study phase, Phase II of this Fast-Track SBIR application, the investigators will conduct a multi-site study of 220 adult patients with CLBP to establish stronger evidence that the product controls pain, reduces negative mood, improves cognition, and protects the brain from shrinking in six months of treatment.
* In November 2024:- Hanmi Pharmaceutical Company Limited- A Randomized, Double-blind, Active-controlled, Non-inferiority, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HCP1004 As Compared to RLD2401 in Chronic Low-Back Pain Patients.
* The total diagnosed prevalent cases of CLBP in the United States were around 31 million cases in 2023.
* The United States contributed to the largest diagnosed prevalent population of CLBP, acquiring ~45% of the 7MM in 2023. Whereas, EU4 and the UK, and Japan accounted for around 40% and 15% of the total population share, respectively, in 2023.
* Among the EU4 countries, Spain accounted for the largest number of Prevalent CLBP (8.6 million) cases followed by Germany (6.3 million), whereas France accounted for the lowest number of cases (5 million) in 2023.
* In 2023, it was estimated that there were around 8 million diagnosed cases in the age group of 70 years and older in the US.
* According to DelveInsight estimates, in 2023 there were approximately 5.5 million diagnosed prevalent cases of chronic low back pain (CLBP) among males and about 4.5 million cases among females in Japan.
* DelveInsight analysis of the age-specific data in the US revealed that the highest number of people affected with CLBP were found in the age group of 70+ years, while people who belonged to the age group 60-69 years were the least affected.
* The leading Chronic Lower Back Pain Companies such as Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, and others.
* Promising Chronic Lower Back Pain Therapies such as Buprenorphine Buccal Film [Belbuca], Adezunap (AP707), Melatonin 10 MG, PP353, CELZ-201-DDT, and others.

Stay ahead in the Chronic Lower Back Pain Therapeutics Market with DelveInsight's Strategic Report @ Chronic Lower Back Pain Market Outlook [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Lower Back Pain Epidemiology Segmentation in the 7MM

* Chronic Lower Back Pain Prevalent Cases
* Chronic Lower Back Pain Diagnosed Prevalent Cases
* Chronic Lower Back Pain Gender-specific Diagnosed Prevalent Cases
* Chronic Lower Back Pain Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Chronic Lower Back Pain epidemiology trends @ Chronic Lower Back Pain Prevalence [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Lower Back Pain Marketed Drugs

* XTAMPZA ER (oxycodone): Collegium Pharmaceutical

XTAMPZA ER (oxycodone) is a semisynthetic opioid. It is currently indicated as an immediate-release product for moderate-to-severe pain and as an extended-release product for chronic moderate-to-severe pain requiring continuous opioid analgesics for an extended period. It is used to manage acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Oxycodone is a highly selective full agonist of the -opioid receptor (MOR), with low affinity for the d-opioid receptor (DOR) and ?-opioid receptor (KOR). Oxycodone and its active metabolites can selectively bind to the -opioid receptor and the kappa and delta-opioid receptors in the central nervous system and periphery and induce a G protein-coupled receptor signaling pathway.

Chronic Lower Back Pain Emerging Drugs

* Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited/Grunenthal

Rexlemestrocel-L, also known as MPC-06-ID, is a Mesoblast's proprietary allogeneic mesenchymal precursor cell (MPC) product candidate, currently in the late stage of development for the treatment of CLBP caused by disc degeneration. It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections, and have no further treatment option other than invasive and costly surgical interventions.

The latest Phase III trial to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment is anticipated to get completed by October 2026.

* Semdexa (SP-102): Scilex Holding Company

Semdexa (SP-102, dexamethasone sodium phosphate) is a non-opioid corticosteroid formulated as a viscous gel injection that is under development to treat lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents, or particulates. Because of these properties, the drug is expected to have a better safety profile than commonly used off-label injected corticosteroids. SP-102 has an ingredient that is a widely used corticosteroid solution.

Get In-Depth Knowledge on Chronic Lower Back Pain Market Trends and Forecasts with DelveInsight @ Chronic Lower Back Pain Treatment Market [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Lower Back Pain Market Outlook

CLBP is a complex process comparable to how each patient has a very individualized disease process the treatment regimen is similarly individualized. There are several different medication classes, each with an exclusive mechanism of action that can help the practitioner target a specific aspect of a patient's pain. Moreover, patient-specific factors are considered when developing a regimen to ensure adherence and improve outcomes.

Scope of the Chronic Lower Back Pain Market

* Coverage- 7MM
* Chronic Lower Back Pain Companies- Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, and others.
* Chronic Lower Back Pain Therapies- Buprenorphine Buccal Film [Belbuca], Adezunap (AP707), Melatonin 10 MG, PP353, CELZ-201-DDT, and others.
* Chronic Lower Back Pain Market Dynamics: Chronic Lower Back Pain Market Drivers and Barriers
* Chronic Lower Back Pain Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight's Comprehensive Chronic Lower Back Pain Market Report @ Chronic Lower Back Pain Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1 Key Insights

2 Report Introduction

3 Chronic Lower Back Pain (CLBP) Market Overview at a Glance

4 Epidemiology and Market Methodology of CLBP

5 Executive Summary of Chronic Lower Back Pain (CLBP)

6 Key Events

7 Chronic Low Back pain (CLBP): Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs

11 Emerging Therapies

12 Chronic Lower Back Pain: Seven Major Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Reimbursement and Market Access

17 Appendix

18 Bibliography

19 Report Methodology

20 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-lower-back-pain-therapeutics-market-size-in-the-7mm-was-usd-6071-million-in-2023-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.